The Miedel Lab uses human biomimetic liver microphysiology systems (MPS) to model both normal and disease-state liver physiology and the main areas of focus are in:
(1) coupling the use of quantitative systems pharmacology (QSP) and liver MPS as a precision medicine platform to identify novel biomarkers and targets for drug discovery for metabolic dysfunction-associated steatotic liver disease (MASLD).
(2) 3D bioprinting of complex liver models.
(3) using MPS to examine the impact of the liver tumor microenvironment on the progression of different cancer types.
The Miedel Lab uses human biomimetic liver microphysiology systems (MPS) to model both normal and disease-state liver physiology and the main areas of focus are in:
(1) coupling the use of quantitative systems pharmacology (QSP) and liver MPS as a precision medicine platform to identify novel biomarkers and targets for drug discovery for metabolic dysfunction-associated steatotic liver disease (MASLD).
(2) 3D bioprinting of complex liver models.
(3) using MPS to examine the impact of the liver tumor microenvironment on the progression of different cancer types.